Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
Johnson Controls (Japan)
h-index: 8
Total citations: 217
Total papers: 31
Homepage:
http://www.jci.com/
Recent papers from Johnson Controls (Japan)
Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study
Journal of Clinical Oncology · 2026
Amivantamab in HPV-unrelated recurrent/metastatic head and neck squamous cell cancer after disease progression on immune checkpoint inhibitor and chemotherapy: Pivotal results from the phase 1b/2 OrigAMI-4 study.
Journal of Clinical Oncology · 2026
Daratumumab plus VRd in Japanese transplant-ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trial
International Journal of Hematology · 2026
Phase 1 safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of pasritamig in Asian population with metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology · 2026
Talquetamab in Japanese patients with relapsed/refractory multiple myeloma in the MonumenTAL-1 study
International Journal of Hematology · 2025
Humanistic burden and medical care patterns of real-world patients with myasthenia gravis in Japan
Frontiers in Neurology · 2025
Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 study
Oral Oncology · 2025
Reporting Frequency of Antipsychotics-Induced Tardive Dyskinesia and Other Extrapyramidal Symptoms: Analysis Based on a Spontaneous Reporting System Database in Japan.
2025
Impact of best response to ibrutinib plus Bendamustine and rituximab on PFS in MCL: a secondary analysis of SHINE
Annals of Hematology · 2025
Assessment of healthcare resource utilization and direct medical cost in relation to treatment length of oral corticosteroids in biologic initiated patients with ulcerative colitis: a Japanese claims database study
Journal of Medical Economics · 2025
Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Switching to Oral Rilpivirine in Combination With Other Antiretroviral Therapy in Virologically Suppressed Children Living With HIV-1 Infection: Forty-eight-week Results From the Phase 2, Open-label, Single-arm, PICTURE Study
The Pediatric Infectious Disease Journal · 2025
Regulatory-required post-marketing database studies in Japan could be leveraged to assess important potential risks as well as identified risks
Frontiers in Pharmacology · 2025
Pharmacokinetics, Safety and Antiviral Activity of Rilpivirine in Antiretroviral-naïve Children With HIV ≥6 to <12 Years Old: Week 48 and Final Analysis of Cohort 2 From the Open-label, Phase 2 PAINT Study
The Pediatric Infectious Disease Journal · 2025
Real‐world safety and effectiveness of guselkumab in patients with psoriasis: A post‐marketing surveillance study through up to week 52 in Japan
The Journal of Dermatology · 2025
Real-world data on combination treatment with bedaquiline in patients with multidrug-resistant pulmonary tuberculosis in Japan: An interim analysis of post-marketing surveillance
Journal of Infection and Chemotherapy · 2025
Harmonic Current Cancellation Method for PMSM Drive System using Resonant Controllers
2018